Ultragenyx Sells Additional 25% Crysvita Royalty Interest to OMERS for $400 Million
Reuters
Nov 05
Ultragenyx Sells Additional 25% Crysvita Royalty Interest to OMERS for $400 Million
Ultragenyx Pharmaceutical Inc. has announced the sale of an additional 25% of its royalty interest in future North American sales of Crysvita® (burosumab) to OMERS Life Sciences for $400 million. This non-dilutive financing agreement will provide Ultragenyx with immediate capital to support four anticipated product launches and strengthen its balance sheet. Under the new agreement, OMERS will begin receiving the additional 25% royalty interest on net sales of Crysvita in the U.S. and Canada starting in January 2028. The total payments to OMERS under this and the previous 2022 agreement are capped at 1.55 times the purchase price. OMERS will continue to receive 30% of Crysvita net sales in North America following the achievement of the 2022 agreement's cap.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568671-en) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.